GSK Bio
NEWS
GlaxoSmithKline CEO Emma Walmsley is eying a big acquisition to spur revenue growth but is making sure that her company will not overpay.
GlaxoSmithKline CEO Emma Walmsley is not done reshaping her leadership team as she continues to overhaul the company’s pharmaceutical division.
Adaptimmune is making strides on becoming a fully integrated cell therapy company behind its T Cell Receptor technology
Vivek Ramaswamy’s Axovant has egg on its face after it was forced to own up to the fact it misreported mid-stage data on a drug it hoped to take into Phase III.
The company will undergo a reorganization that includes the termination of a number of sales representatives.
Bruno Strigini, the CEO of Novartis Oncology, plans to exit the company’s Executive Committee by Dec. 31, 2017, and leave entirely in early 2018.
GlaxoSmithKline will scout for deal opportunities in cancer medicine, as well as immunology, as the drugmaker seeks to rebuild its presence in oncology, its new head of pharmaceuticals told Reuters.
Glaxo has a bold future planned for its R&D facility in Maryland.
A filing with the SEC indicates that Glaxo now has a 13 percent stake in Spero Therapeutics.
JOBS
IN THE PRESS